Showing Results for: “diabetes exercise”

Data Addresses Gaps in Preventive Prescriptions Therapy, Emphasizing the Importance of Multifaceted Interventions Today, findings from the COORDINATE-Diabetes trial demonstrated that multi-disciplinary care between cardiologists, diabetes specialists and other team members can significantly increase the prescriptions of evidence-based therapies to help treat patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), commonly known as heart disease. The trial was presented as a late-breaking symposium today at the 83rd Scientific Sessions of the American

Reality show style competition showcases novel diabetes business ideas with potential funders as part of ADA 83 rd Scientific Sessions Today, the American Diabetes Association® (ADA) announced the winners of its inaugural pitch competition at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA. The first-ever Innovation Challenge highlighted six business concepts for diabetes care before a panel of potential funders, with the goal of connecting innovators and startup companies with transformative solutions and ideas. The winners, Minutia, Oregon Health &

American Diabetes Association Symposium Demonstrates Benefits of Once Weekly Drug for Weight Loss and Glycemic Control Today, findings from SURMOUNT-2, a study of tirzepatide in participants with type 2 diabetes who have obesity were announced, demonstrating more weight loss in individuals with diabetes than any other medication to date. The results were presented at the 83rd Scientific Sessions of the American Diabetes Association ® (ADA) in San Diego, CA and were simultaneously published in The Lancet . Obesity impacts 650 million people worldwide including nearly half of all Americans and

First-of-Its-Kind Study Compares Open-Source Automated Insulin Delivery to Sensor-Augmented Pump Therapy Results from the CREATE Trial demonstrated open-source automated insulin delivery (AID) systems are a safe and effective therapy for people with type 1 diabetes. Findings from the randomized controlled trial (RCT) comparing open-source AID to sensor-augmented pump therapy (SAPT) were presented today at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA). Open-source AID systems were developed to reduce the burden of living with diabetes by combining an insulin pump

The American Diabetes Association® (ADA) applauds Alabama Governor Kay Ivey today for signing House Bill 249, legislation that will cap insulin co-sharing at $100 per month for those on state-regulated health plans, without regard to the policy deductible, and regardless of the quantity or type of insulin needed to fill the insured patient's prescription. Bill sponsor, Representative Paul Lee, Chairman of the House Health Committee and Senator Tom Butler, Chairman of the Senate Veteran’s and Military Affairs Committee provided leadership on this important legislation to reduce the burden of

Today, the American Diabetes Association® (ADA) applauded Kentucky Governor Andy Beshear for signing legislation that will cap insulin co-pays at $30 per month, regardless of the quantity or type of insulin needed to fill the insured patient's prescription. Governor Beshear and bill sponsor Representative Danny Bentley provided expert leadership on this important legislation to reduce the burden of insulin costs for people living with diabetes. Kentucky joins 14 other states as well as the District of Columbia that have enacted insulin copay caps to reduce costs of this life-saving drug.

The Teplizumab Prevention Trial has given validity to the concept that immune therapy can delay the diagnosis of type 1 diabetes (T1D), according to findings presented at a symposium entitled “New Therapeutic Approaches and Insights for Type 1 Diabetes” today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Family members of someone with T1D have a 15 times greater risk of developing T1D than individuals from the general population. Testing can determine the presence of autoantibodies, indicating risk for T1D, and the